Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Pfizer's Ulcerative Colitis Candidate Aces Late-Stage Study

Pfizer Inc (NYSE:PFE) has announced topline results from a Phase 3 study of etrasimod in moderately to severely active ulcerative colitis (UC). In the study, etrasimod patients achieved statistically significant improvements in the primary endpoint of clinical remission at week 12 compared with placebo. Statistically significant improvements were achieved in all key secondary…

Benzinga

Moderna to seek emergency authorization for COVID-19 vaccine use for kids under 6

Kids, prep those arms.

Tribune News Service

When will the Covid spring booster jab be available for young people?

Rollout has begun across the UK for the Covid spring booster. Here's who is eligible for the second booster dose and when young people will be able to get their fourth coronavirus vaccine

Daily Mirror

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer CEO pushes yearly Covid shots

Assertions by pharmaceutical company executives have created pressure for scientists and politicians to take action

Salon

Moderna says its low-dose COVID shots work for kids under 6

Moderna says its COVID-19 vaccine works in babies, toddlers and preschoolers

The Independent UK

The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

FDA advisory panel to discuss additional Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Docs unconvinced we need two boosters

Vaccine-makers are seeking approval for a second booster. Some doctors don’t think the evidence is strong

Salon

Moderna Bolsters Its Pipeline With Two New mRNA-Based Vaccine Programs

Moderna Inc (NASDAQ:MRNA) expands its mRNA pipeline with two new development programs ahead of Annual Vaccines Day, building on Moderna's experience with Spikevax, its COVID-19 vaccine. The development programs include a combination respiratory vaccine candidate and a new program against all four endemic human coronaviruses (HCoV). First, Moderna is launching a respiratory combination…

Benzinga

Pfizer Recalls Some Lots Of Hypertension Med Due To Potential Cancer-Causing Impurity

Pfizer Inc (NYSE:PFE) voluntarily recalls Accuretic (quinapril HCl/hydrochlorothiazide) and two authorized generic versions due to the presence of nitrosamine, N-nitroso-quinapril, above an acceptable level. Pfizer will recall six lots of Accuretic tablets, one lot of quinapril and hydrochlorothiazide tablets, and four lots of quinapril HCl/ hydrochlorothiazide tablets. Nitrosamines are common in water and…

Benzinga

Time for an Operation Warp Speed to Develop Pan-Coronavirus Vaccines

Meanwhile the FDA dawdles over second boosters as new COVID-19 wave approaches

Reason

No funds to buy fourth Covid vaccine dose for all Americans, White House warns

Funding for coronavirus aid stalled in Congress leaving vaccine and therapeutics purchases lacking

The Independent UK

Pfizer CEO pushes yearly shots for COVID. Not so fast, experts say

When Pfizer CEO Albert Bourla said March 13 that all Americans would need a second booster shot, it struck many COVID-19 experts as a self-serving remark without scientific merit. It also set off spasms of doubt over the country’s objectives in its fight against the coronavirus.

Tribune News Service

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Novartis Suspends Some Investment, Business Activities In Russia

Novartis AG (NYSE:NVS) will suspend capital investments, media advertising, and other promotional activities in Russia but remain committed to providing access to its medicine there. "Novartis condemns the war in Ukraine," it said in a statement, adding that "while we remain committed to providing access to our medicine in Russia, we responsibly…

Bangkok Post

Songkran boost for seniors

The Ministry of Public Health is aiming to administer a third booster shot to 70% of the country's elderly population ahead of the Thai New Year holiday next month, as they face a greater risk of infection and death from the coronavirus.

The Guardian - AU

With Covid cases surging across Australia, will a fourth vaccine dose be required?

How effective would a second booster be? Who is eligible now? Why are third dose numbers lagging? Experts explain

Los Angeles Times

California could see coronavirus uptick this spring because of omicron subvariant BA.2

LOS ANGELES — Coronavirus cases are on the upswing worldwide, prompting some officials to warn that California could see increases this spring because of the omicron subvariant BA.2 even though cases so far have been modest.

Get all your
news in one place.

100's of premium titles.
One news app.

Businessweek

The Future of Boosters Is Somewhere Between Unnecessary and Urgent

Until there’s a universal coronavirus vaccine, the future of additional shots is a murky work in progress—but more rounds seem increasingly likely.

Nottingham Post

4th Covid jab to be offered this week as Spring booster rollout begins

The NHS said its Covid-19 vaccination programme will contact people when it is their turn to be vaccinated

Financial Times

Will AI turbocharge the hunt for new drugs?

Advocates point to the pandemic as proof of its value in healthcare even as critics dismiss its use in drug discovery as ‘hype’

The Times of India

Hyderabad cos get licence for Pfizer’s Covid pill

HYDERABAD: Apart from Hyderabad-based pharma major Aurobindo Pharma Limited, other city-based pharma players like Granules India Ltd, MSN Group and SMS Pharmaceuticals too have received licences from the UN-backed Medicines Patent Pool (MPP) to manufacture and supply a generic version of nirmatrelvir, a key component of Pfizer’s oral Covid-19 drug…

Salon

Big Pharma won't let the vaccine out

Waiving Covid vaccine patents would help poor countries fight the disease. Pharma giants won't let that happen

Benzinga

Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters

Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,

The Independent UK

Marjorie Taylor Greene condemns Covid boosters by claiming polio vaccine is only one jab – but it actually takes four

‘I think the question we all should ask is “when does it stop?” and “when are enough vaccines enough?”’ Greene said

1 … 60 61 62 63

People

Joe Biden

67,835 stories

Marjorie Taylor Greene

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.